Blog
RSS FeedPosted by Michael Wonder on 14 Aug 2023
Insurers won’t cover new Alzheimer’s treatment for some customers
12 August 2023 - Some private insurers are balking at paying for the first drug fully approved to slow mental ...
Posted by Michael Wonder on 11 Aug 2023
PHARMAC proposes widening access to a brain cancer treatment to help reduce the impact of a discontinuation
11 August 2023 - PHARMAC is proposing to widen access to temozolomide, an oral anti-cancer treatment, for people with a type ...
Posted by Michael Wonder on 09 Aug 2023
Insurers can’t avoid covering weight loss drugs forever
8 August 2023 - New data illustrating the health benefits of Novo Nordisk’s obesity drug Wegovy puts insurers in the increasingly ...
Posted by Michael Wonder on 08 Aug 2023
Major US health systems expect to offer Alzheimer's drug Leqembi in a few months
7 August 2023 - Five major US health systems said they would offer Eisai and Biogen's promising new Alzheimer's drug ...
Posted by Michael Wonder on 07 Aug 2023
Alberta will cover pricey drug believed to extend and enhance lives of ALS patients
7 August 2023 - People diagnosed with ALS are usually given two to five years to live. ...
Posted by Michael Wonder on 07 Aug 2023
GP leaders advise practices not to prescribe cholesterol lowering drug inclisiran
1 August 2023 - Local GP leaders across the south of England have told practices not to follow the NHS’s ...
Posted by Michael Wonder on 06 Aug 2023
Free the PrEP - over the counter access to HIV pre-exposure prophylaxis
5 August 2023 - Several barriers to access to preexposure prophylaxis for HIV could be alleviated by making it available over ...
Posted by Michael Wonder on 03 Aug 2023
Jazz Pharmaceuticals enters into letter of intent with the pan-Canadian Pharmaceutical Alliance for Rylaze, helping address the unmet need of acute lymphoblastic leukaemia and lymphoblastic lymphoma patients across Canada
2 August 2023 - Jazz Pharmaceuticals today announced that the Company has entered into a letter of intent with the pan-Canadian ...
Posted by Michael Wonder on 01 Aug 2023
PHARMAC considers access criteria for COVID-19 anti-viral treatments
1 August 2023 - PHARMAC is consulting on changes to the access criteria for all COVID-19 anti-viral treatments to include ...
Posted by Michael Wonder on 01 Aug 2023
Global sarcoma therapy now listed on Pharmaceutical Benefits Scheme
31 July 2023 - Yondelis (trabectedin) demonstrates 45% reduction in risk of disease progression or death versus dacarbazine. ...
Posted by Michael Wonder on 31 Jul 2023
Fair allocation of scarce CAR T-cell therapies for relapsed/refractory multiple myeloma
31 July 2023 - The treatment landscape for relapsed/refractory multiple myeloma has undergone an immunotherapeutic breakthrough with the introduction of ...
Posted by Michael Wonder on 31 Jul 2023
Schedule of Pharmaceutical Benefits - 1 August 2023
1 August 2023 - The August 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 31 Jul 2023
New Zealand Pharmaceutical Schedule - 1 August 2023
1 August 2023 - The August 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 27 Jul 2023
Obesity drugs don't make WHO's essential list, but Ebola, MS drugs added
26 July 2023 - Obesity drugs will not join the World Health Organization's latest essential medicines list, but treatments for ...
Posted by Michael Wonder on 27 Jul 2023
World Health Organization publishes updated essential medicines list
27 July 2023 - Three medicines that can delay or slow multiple sclerosis disease progression have been included in the Essential ...